Stübner U P, Toth J, Marks B, Berger U E, Burtin B, Horak F
Ear-Nose-Throat University Clinic, Vienna, Austria.
Arzneimittelforschung. 2001 Nov;51(11):904-10. doi: 10.1055/s-0031-1300135.
The aim of this study was to compare the decongestant properties and tolerability of the sympathomimetic xylometazoline hydrochloride 0.1% (CAS 1218-35-5, XMZ) and an oral formulation of cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg (CAS 83881-51-0 and 90-82-4, CTZ/PSE; Cirrus). Thirty-six asymptomatic patients suffering from perennial allergic rhinitis from house dust mite were randomized to this open two-period crossover study. Patients received the study medications for four days each. In each period, treatments were taken twice a day. On day 1 in each period, immediately after the first dose of medication, patients were challenged with Dermatophagoides pteronyssinus extract 1 in the Vienna Challenge Chamber for 5 h. Primary efficacy parameters were nasal congestion evaluated by digital analysis of nasal cavity photographs and nasal airflow. Furthermore amounts of nasal secretions, nasal and ocular symptoms were recorded. In addition, 5 independent Ear-Nose-Throat specialists also assessed nasal cavity photographs. Statistical analyses were conducted at the 5% level of significance. Digital analysis of the nasal cavity photographs as well as nasal airflow measurements did not differentiate XMZ from CTZ/PSE. Ratings of the photographs of the nasal cavity emphasized the rapid onset of XMZ. No clinically relevant adverse events were recorded. This rapid onset of action but short-lived effect of topical xylometazoline 0.1% should be balanced against the consistent and prolonged effect of systemic cetirizine/pseudoephedrine combination in the treatment of perennial allergic rhinitis as no significant differences between these 2 medications were noted regarding their decongestant properties. With the exception of nasal obstruction, all subjective symptoms as well as the global condition were significantly better under CTZ/PSE. Amounts of nasal secretions during these sessions were significantly lower with CTZ/PSE.
本研究旨在比较拟交感神经药0.1%盐酸赛洛唑啉(CAS 1218-35-5,XMZ)与5 mg盐酸西替利嗪和120 mg盐酸伪麻黄碱口服制剂(CAS 83881-51-0和90-82-4,CTZ/PSE;Cirrus)的减充血特性和耐受性。36名因屋尘螨引起常年性变应性鼻炎的无症状患者被随机纳入这项开放的两阶段交叉研究。患者每种研究药物各服用4天。在每个阶段,治疗均为每日2次。在每个阶段的第1天,在首次给药后立即在维也纳激发试验箱中用1型粉尘螨提取物对患者进行5小时的激发试验。主要疗效参数为通过鼻腔照片数字分析和鼻气流评估的鼻充血情况。此外,还记录了鼻分泌物量、鼻部和眼部症状。另外,5名独立的耳鼻喉科专家也对鼻腔照片进行了评估。统计分析在5%的显著性水平上进行。鼻腔照片的数字分析以及鼻气流测量未区分XMZ和CTZ/PSE。鼻腔照片评分强调了XMZ起效迅速。未记录到临床相关不良事件。在治疗常年性变应性鼻炎时,0.1%局部用赛洛唑啉起效迅速但作用短暂的特点应与全身性西替利嗪/伪麻黄碱组合持续且持久的效果相权衡,因为这两种药物在减充血特性方面未观察到显著差异。除鼻塞外,在CTZ/PSE治疗下所有主观症状以及整体状况均明显更好。在这些疗程中,CTZ/PSE治疗时的鼻分泌物量显著更低。